Form 4: Aurinia Pharmaceuticals Director Kevin Tang Increases Stake with Series of Share Purchases

Director Kevin Tang reports several purchases of Aurinia Pharmaceuticals (AUPH) common shares, significantly increasing his indirect holdings.

Summary

• Kevin Tang, a director of Aurinia Pharmaceuticals, has reported a series of purchases of AUPH common shares.
• These transactions occurred between February 28, 2025, and March 4, 2025.
• The purchases were made at prices ranging from $7.47 to $8.10 per share.
• The total number of shares indirectly beneficially owned by Mr. Tang increased from 8,828,780 to 10,029,500 as a result of these transactions.
• The shares are held indirectly through Tang Capital Partners, LP (TCP), Tang Capital Partners International, LP (TCPI), and Tang Capital Partners III, Inc. (TCP III).
• Mr. Tang has a pecuniary interest in the shares held by these entities.

Sentiment

Score: 7

Explanation: The document indicates a director is increasing their stake in the company, which is generally viewed as a positive signal. However, it's important to consider the context and reasons behind the purchase.

Positives

• A director's increased investment in the company may signal confidence in the company's future prospects.
• The purchases demonstrate a willingness to invest personal funds in Aurinia Pharmaceuticals.
• The increased stake could align the director's interests more closely with those of other shareholders.

Industry Context

Director share purchases are common and closely watched as indicators of management's sentiment about the company's prospects. Increased ownership can be seen as a positive signal.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign.
• The increased ownership could potentially influence the company's strategic decisions.

Key Dates